These findings revealed for the first time that EGR1 is a key transcription factor regulating KLK1 expression, providing a molecular mechanism at the transcriptional level for KLK1 dysregulation, suggesting that the EGR1‐KLK1 axis may inhibit inflammatory‐cancer transformation by regulating pathways such as PTEN, providing a new strategy for targeted intervention. The gene discussed is PTEN; the disease is cancer.